T8636 |
Ibrutinib deacryloylpiperidine
|
330786-24-8
|
99.8%
|
|
Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
|
T4337 |
PCI 29732
|
330786-25-9
|
99.79%
|
|
PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
|
T1835 |
Ibrutinib
|
936563-96-1
|
99.76%
|
|
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
|
TQ0236 |
Tirabrutinib
|
1351636-18-4
|
99.75%
|
|
Tirabrutinib (GS-4059) (ONO-4059) is an orally active Bruton’s Tyrosine Kinase (Btk) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM....
|
T17098 |
Tilfrinib
|
1600515-49-8
|
99.73%
|
|
Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.
|
T14323 |
ARQ 531
|
2095393-15-8
|
99.59%
|
|
ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectiv...
|
T10629 |
Btk inhibitor 2
|
1558036-85-3
|
99.49%
|
|
Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.
|
T63272 |
Edralbrutinib
|
1858206-58-2
|
99.47%
|
|
Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and lymphat...
|
T12317 |
Orelabrutinib
|
1655504-04-3
|
99.44%
|
|
Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
|
T3626 |
Acalabrutinib
|
1420477-60-6
|
99.43%
|
|
Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon a...
|
T1976 |
RN486
|
1242156-23-5
|
99.38%
|
|
RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
|
T16730 |
Remibrutinib
|
1787294-07-8
|
99.34%
|
|
Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50...
|
T9706 |
BTK inhibitor 17
|
1858206-76-4
|
99.29%
|
|
BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.
|
T6921 |
ONO-4059 analog
|
1351635-67-0
|
99.25%
|
|
ONO-4059 analog (ONO-WG-307)ue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
|
T7584 |
Zanubrutinib
|
1691249-45-2
|
99.24%
|
|
Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).
|
T9125 |
Tolebrutinib
|
1971920-73-6
|
99.2%
|
|
Tolebrutinib (PRN2246) is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells ...
|
T5138 |
BMS-986142
|
1643368-58-4
|
99.13%
|
|
BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
|
T2302 |
CNX-774
|
1202759-32-7
|
99.1%
|
|
CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
|
T35330 |
BTK inhibitor 1
|
2230724-66-8
|
99.06%
|
|
BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.
|
TQ0230 |
BTK IN-1
|
1270014-40-8
|
98.98%
|
|
BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
|